Published on
13:02 GMT
Merck Keytruda approved by USFDA for Advanced Head and Neck Cancer
Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of adult patients with resectable …
Source:
Medical Dialogues
-
Indeterminate
